This morning, Eli Lilly announced that evacetrapib, its experimental drug to raise good cholesterol, failed to prevent patients from getting heart attacks and strokes in a large clinical trial. It is the third similar medicine to fail in expensive studies by three different drugmakers, dashing hopes for a new kind of treatment that might have helped millions of patients and calling into question the risky tendency of pharmaceutical executives to spend hundreds of millions of dollars on studies that have a low probability of succeeding.
Read Full Article »
